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Abstract
Background: Mazabraud’s syndrome is defined as the association between fibrous dysplasia and intramuscular
myxomas. The syndrome was first described in 1967 and, up until now, less than 100 cases have been reported
worldwide. Here we report the association between this rare syndrome and thyroid cancer. When a malignant
disease occurs in a patient affected by this syndrome, the differential diagnosis between benign and malignant
bone lesions should be undertaken carefully.
Case presentation: We report the case of a 57-year-old Caucasian male, admitted for diffuse bone pain localized in
the left leg and for the presence of an indolent, slow-growing mass in the left shoulder. The patient also presented
with a thyroid nodule, highly suggestive of a malignancy. The radiologic examination showed multiple osteolytic
lesions. The suspicion of multiple myeloma or bone metastases arising from a thyroid cancer was considered.
Electrophoresis of proteins was negative and therefore excluded the diagnosis of multiple myeloma; the thyroid
surgery was indicated. Thyroidectomy confirmed the papillary thyroid carcinoma, and the bone lesions were
considered to be metastases from the thyroid cancer. After surgery, under thyroid-stimulated hormonal conditions,
the patient underwent radioiodine therapy and a post-therapy radioiodine whole body scan. The lack of
radioiodine uptake, both in the bone lesions and shoulder mass, suggested the possibility of less differentiated,
non-avid radioiodine lesions, or the absence of any relation between pathologies. Considering the low level of the
specific tumor marker, thyroglobulin, a bone biopsy and resection of the shoulder mass were indicated. The final
diagnosis was intramuscular myxoma with polyostotic fibrous dysplasia in the deltoid muscle (Mazabraud’s
syndrome). A completely incidental cerebral tumor lesion was also discovered.
Conclusion: During the evolution of a malignant disease, Mazabraud’s syndrome, known as the association of
intramuscular myxoma with fibrous dysplasia, should be considered in the differential diagnosis of bone metastasis.
This is the first report in the literature of Mazabraud’s syndrome occurring in a patient with thyroid cancer.
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Background
In 1967, the French physician Mazabraud described the
association of intramuscular myxoma with fibrous dyspla-
sia for the first time, naming the syndrome after himself
[1, 2]. Fibrous dysplasia is a benign lesion in intramedul-
lary bone. It can be found in two forms: a polyostotic (dis-
seminated bone lesions) and a monostotic form (unique
bone lesion) [3]. Symptoms include localized tumoral and
intermittent pain or even pathological fractures. The dif-
ferential diagnosis includes neurofibromatosis, multiple
myeloma, endochondromatosis, hyperparathyroidism and
McCune–Albright syndrome [4]. Intramuscular myxomas
represent benign mesenchymal tumors associated with
the polyostotic form of fibrous dysplasia in most women.
The incidence of Mazabraud’s syndrome is <1/1,000,000
[4–6], with only 68–80 cases reported in the medical lit-
erature worldwide [1, 2]. The official Orphanet report,
published in July 2015 confirms the presence of 54 cases
published in the literature (ORPHA number 57782) [5].
The molecular diagnosis involves mutations in the
GNAS1 gene, which encodes for an alpha subunit of a G
protein [7].
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Treatment of Mazabraud’s syndrome includes the specific
treatment of the fibrous dysplasia when complications ap-
pear: pathological bone fractures treated using osteosynth-
esis, or when sarcoma transformation occurs, exceptionally,
specific treatment for the malignant tumor. Intramuscular
myxomas benefit from an excision and control of local and
regional lesions.
We present the case of a 57-year-old Caucasian
male with Mazabraud’s syndrome that was associated
with a papillary thyroid carcinoma [8, 9]. A papillary
thyroid cancer has been described in the literature,
although in association with the McCune-Albright
syndrome [7].
Case presentation
A 57-year-old male was referred to the Institute of Oncol-
ogy Cluj-Napoca for a second opinion, with suspicion of a
multiple myeloma. The patient presented with diffuse
post-traumatic pain in the left thorax and the left tibial
diaphysis. The clinical exam revealed a tumor lesion local-
ized in the left deltoid region and another one in the an-
terior cervical region, suggestive of thyroid nodules. Right
lateral cervical enlarged lymph nodes were also described.
Conventional radiological examination highlighted areas
of osteolysis in the right IVth costal arch and areas of
osteolysis with ballooning in the left IVth, Vth and VIIth
costal arches, as well as deformation and erosion of the
cortical area of the bone.
Radiography of the tibia revealed a left tibia diaphysis
with an irregular aspect of the compact bone (Fig. 1).
Suspicion of a multiple myeloma or metastases in the
bones with an undetermined origin was raised. Immuno-
fixation electrophoresis of proteins was negative and
therefore excluded a diagnosis of multiple myeloma. The
patient was directed to the nuclear medicine department
for a bone scintigraphy, which revealed the pathological
uptake of tracer at the level of the costal arches and in
the left diaphysis of the tibia (Fig. 2).
A blood sample was collected in order to deter-
mine the levels of tumor markers, which were at
physiological normal levels: CA 19-9 = 25.2 U/mL
(N.V. <27), CEA = 2.2 ng/mL (N.V. smokers <3.4;
non-smokers <4.3), PSA = 1.31 ng/mL (N.V. <60 years
old ≤3.1). Whole-body MRI showed multiple bone le-
sions localized at the level of the costal arches, left tibia,
and left pubic branch, and an incidental tumor localized
in the clivus that extended to the right sphenoid sinus
(Fig. 3). In addition, there were multiple suspicious lymph
nodes in the neck and in the right supraclavicular area
and an inhomogeneous lesion in the right thyroid lobe
(Fig. 4). The patient, at this point, was tentatively diag-
nosed to have thyroid cancer with bone and cutaneous
metastases.
Blood samples were collected to determine thyroid
stimulating hormone (TSH) and free-thyroxine-FT4
levels, which were found to be within normal limits.
The thyroid peroxidase (TPO) test was also negative,
thereby excluding a chronic lymphocytic thyroiditis.
Calcium and parathyroid hormone (PTH) levels were
also within normal limits, which excluded a parathy-
roid pathology, while a normal calcitonin level excluded a
medullary thyroid carcinoma. Biopsy of one of the right
cervical lymph nodes was performed and histology re-
vealed a papillary thyroid cancer lymph node metastasis.
Immunohistochemistry (IHC) of TTF-1 and thyroglobulin
(TG) were positive in tumor cells. A total thyroidectomy
and right selective lymphadenectomy were performed.
This confirmed the diagnosis of a papillary thyroid carcin-
oma with lymph node metastasis (T3N1bMx stage IVA)
(Fig. 5).
Radioiodine therapy was indicated and given at a total
dose of 96 mCi (3.55 GBq). Figure 6 shows a whole body
scan (WBS) at 48 h after the radioiodine cure and shows
pathologic radioiodine uptake in the right thyroid bed,
within the mediastinum area and in a left lateral cervical
lymph node, but there was no uptake in the bone. There
Fig. 1 Tibial radiograph showing bone dysplasia in the middle and
distal parts of the diaphysis
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were at least three possibilities as to what the bone
lesions were: 1) a less differentiated thyroid tumor,
confirmed by the relatively low level of the specific
tumor marker, TG = 28 ng/mL (N.V. <0.04 ng/mL in
cured thyroid cancer patients, and negative for anti-
TG antibodies) determined under stimulated TSH; 2)
non-avid radioiodine lesions, confirmed by the lack of
radioiodine uptake, both in the bone lesions and in
the shoulder mass; and 3) the absence of any relation
between the bone, the muscle pathologies and the
thyroid cancer.
A biopsy of the shoulder tumor lesion was taken from
the left deltoid area and the histology exam revealed a
macroscopic white-translucent specimen of 3.5/3/2 cm,
and of gelatinous consistency, without any areas of necro-
sis. Microscopic examination revealed tumor proliferation
consisting of fusocellular and star cells, without any
nuclear atypia and mitosis in a myxoid stroma. Tumor
proliferation infiltrated into the rib muscles and resected
margins came in contact with proliferating tumor cells.
IHC was negative for S100, actin and desmin; the histologic
Fig. 4 MRI of the cervical region showing the right thyroid lobe
with a nodular structure and right cervical lymph nodes highly
suspicious for malignancy
Fig. 3 Brain MRI showing a tumor in the clivus and involvement of
sphenoid bone
Fig. 2 Whole body bone scintigraphy using Tc-99m MDP, showing
pathologic uptake of tracer in thorax, pelvic area and left tibia
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aspect and IHC were specific for an intramuscular myxoma
(Fig. 7). The association between the histology of the
tumor and the bone lesions, with aspects of fibrous
dysplasia, led to the diagnosis of Mazabraud’s syndrome.
Biopsy of the tibia confirmed the diagnosis.
At 2 years after surgery and irradiation, patient sta-
tus revealed that: clinical tests and thyroid ultrasound
were negative, antithyroglobulin (anti-TG) was <10
UI/mL (N.V. ≤115), TSH was 21.91 μUI/mL, TG was
0.82 ng/mL (N.V. athyroid patients <0.04) and I-131
WBS was negative (Fig. 8). The patient was therefore
considered cured of his thyroid cancer and yearly
follow-up was implemented; the bone lesions attrib-
uted to osseous dysplasia were stable.
During the follow-up at 3 years after the initial
diagnosis of Mazabraud’s syndrome a bone scintig-
raphy was performed and confirmed the bone tumor
lesions already known, as well as a new lesion in the
left ankle articulation, further corroborating the diag-
nosis of Mazabraud’s syndrome (Fig. 9). No clinical
signs of relapse were noted in the left deltoid area.
No genetic testing for mutations in the GNAS1 gene
was performed because it was not available nation-
ally. The cerebral lesion described in the MRI was
not biopsied, being refused by patient, and was there-
fore strictly monitored by the neurosurgery specialist.
Discussion
The medical case presented is typical of Mazabraud’s
syndrome, as described in the literature, however, the
association with a malignant disease, seriously compli-
cated the medical diagnosis and treatment.
Fibrous dysplasia has no predilection for the axial
skeleton or the appendicular one. Statistics show that
fibrous dysplasia has an incidence of 7 % of all be-
nign bone lesions [9]. In the case presented, the poly-
ostotic form was predominant, with lesions being
situated in the diaphysis-metaphysis region, pelvis and
the costal arches, which occurs with a frequency of
15 % of all lesions. The trigger for this type of lesion
is a genetic mutation in the GNAS1 gene situated
on chromosome 20q that encodes the alpha subunit
of a G protein, which plays an important role in cell
proliferation [8]. Fibrous dysplasia can also occur in
the McCune–Albright syndrome, in which café-au-lait
spots and endocrine disorders appear (nodular goiter,
diabetes, early puberty and others) [4].
There are usually multiple intramuscular myxomas that
occur in Mazabraud’s syndrome that appear before any
bone lesion [10]. The mean age at which Mazabraud’s
syndrome is diagnosed is 47 years, and the disease is
predominant in the female population [8]. The most
frequent pathologies associated with Mazabraud’s syn-
drome are benign thyroid diseases and early puberty.
When a malignant tumor such as thyroid cancer is sus-
pected, the presence of any other tumors in the brain,
bones or soft tissues should be considered as potential
metastases, unless other pathologies are ruled out. In this
particular case, although a possible association between
the two entities of myxoma and osseous dysplasia in
Mazabraud’s syndrome is uncommon, it allowed the
Fig. 5 Histopathology of the thyroid gland showing a papillary thyroid carcinoma (H&E staining, 100× magnification). Tumor cells have specific
nuclear changes and form follicles and papillary structures. A small psammomatous body is visible (indicated by the black arrow)
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clinician to select the correct radical therapeutic strategy
to treat the thyroid pathology.
The imaging techniques used for the diagnosis of
Mazabraud’s syndrome involved conventional radiology to
outline the bone lesions from the fibrous dysplasia using
the “ground-glass” aspect and presenting areas of bone
sclerosis [2]. Bone scintigraphy was indicated to outline
the polyostotic form and the implication of multiple bone
structures. MRI was used to detect muscle tumor lesions
and to find new lesions that were not clinically evident [1].
Microscopy of the intramuscular myxoma was spe-
cific: hypocellularity, with a myxoid stroma, stellar as-
pect of the cells and the absence of nuclear atypia
and of the necrosis [2].
There is no specific treatment for Mazabraud’s syn-
drome. A follow-up of the bone pathology was indicated
in order to detect a possible malignant transformation.
Intramuscular myxomas can be excised when they cause
local pain [9]. The association with a malignant disease is
very challenging, especially if the genetic test is missing.
In the present clinical case, the specific uptake of
radioiodine into only normal and tumoral thyroid cells
during the WBS was the main reason for understanding
the non-thyroid origin of the bone lesions. The chance
of this case was the good prognostic of the malignant
disease, which was considered for radical treatment. The
limited information about Mazabraud’s syndrome and
its low incidence might lead to the use of the wrong
therapeutic strategy if other bone metastatic malig-
nant diseases are involved.
Conclusions
Mazabraud’s syndrome continues to be a very rare
disease, with <100 cases worldwide. Therefore, in
assessing a bone lesion associated with a malignant
disease, we should be warned about its features, con-
sidering that the confusing clinical presentation might
result in inappropriate staging and therapy for a can-
cer patient.
Consent
Written informed consent was obtained from the pa-
tient for publication of this Case report and any ac-
companying images. A copy of the written consent is
available for review by the Editor of this journal.
Fig. 6 Whole body scan (WBS) at 48 h after radioiodine I-131
therapy showing pathologic uptake in the thyroid bed and left
cervical lymph nodes
Fig. 7 Histopathology of an intramuscular myxoma from a deltoid
tumor (H&E staining, 25× magnification). Paucicellular tumor with
myofibroblasts and fibroblasts embedded in a myxoid stroma.
Mitotic activity is inconspicuous. Skeletal muscle fibers can be seen
on the right
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